Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
NCT06033586
·
clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
46
Enrollment
INDUSTRY
Sponsor class
Conditions
Polycythemia Vera
Interventions
DRUG:
Open-label rusfertide
Sponsor
Protagonist Therapeutics, Inc.